Expanding targets for a metabolic therapy of cancer: L-Asparaginase

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 1, 2012, Pages 4-13

  Covini, Daniele ^a   Tardito, Saverio ^b   Bussolati, Ovidio ^b   Chiarelli, Laurent R ^a   Pasquetto, Maria V ^a   Digilio, Rita ^a   Valentini, Giovanna ^a   Scotti, Claudia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Acute lymphoblastic leukaemia; Amino acid metabolism; Asparagine; Cancer; Glutaminase; Glutamine; L asparaginase

Indexed keywords

ASPARAGINASE; ASPARAGINE; GLUTAMINE; ROSMARINIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; AGITATION; AMINO ACID SUBSTITUTION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGICAL PRODUCTION; BLEEDING; CANCER THERAPY; CONVULSION; DEPRESSION; DISORIENTATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; ENZYME MODIFICATION; FEVER; HALLUCINATION; HUMAN; LIVER FUNCTION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SIDE EFFECT; SOMNOLENCE; VOMITING;

EID: 83455236523     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212798358001     Document Type: Article

References (115)

1. Clementi A. La desamidation enzmatique de I'asparagine chez les differentes especes-animals et la signification physiologique de sa presence dans l'organisme. Arch Intern Physiol 1922; 19: 369-98.
2. Kidd J. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953; 98: 565-82.
3. Kidd J. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: Histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: Discussion. J Exp Med 1953; 98: 583-606.
4. Broome J. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature 1961; 191: 1114-5.
5. Broome J. Evidence that the L-asparaginasc of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the Lasparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 1963; 118: 99-120.
6. Broome J. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J Exp Med 1963; 118: 121-47.
7. Tsuji Y. Studies on the amidase. IV. Supplemental studies on the amidase action of the bacteria. Japan Arch Internal Med 1957; 4: 222-4.
8. Wade HE, Elsworth R, Herbert D, Keppie J, Sargeant K. A new Lasparaginase with antitumour activity? Lancet 1968; 2: 776-7.
9. Michalska K, Jaskolski M. Structural aspects of L-asparaginases, their friends and relations. Acta Biochim Pol 2006; 53: 627-40.
10. Sanches M, S. K, Polikarpov I. Structure, Substrate Complexation and reaction Mechanism of Bacterial Asparaginases. Curr Chem Biol 2007; 1: 75-86.
11. Yun MK, Nourse A, White SW, Rock CO, Heath RJ. Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I. J Mol Biol 2007; 369: 794-811.
12. Aghaiypour K, Wlodawer A, Lubkowski J. Structural basis for the activity and substrate specificity of Erwinia chrysanthemi Lasparaginase. Biochemistry 2001; 40: 5655-64.
13. Swain AL, Jaskolski M, Housset D, Rao JK, Wlodawer A. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci USA 1993; 90: 1474-8.
14. Lubkowski J, Palm GJ, Gilliland GL, Derst C, Rohm KH, Wlodawer A. Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. Eur J Biochem 1996; 241: 201-7.
15. Dodson G, Wlodawer A. Catalytic triads and their relatives. Trends Biochem Sci 1998; 23: 347-52.
16. Illarionova N, Petrov L, Olennikova L, Roshchin S, Pasechnik V. Study of the secondary structure of L-asparaginase over a broad range of pH values. Mol Biol (Mosk) 1980; 14: 951-5.
17. Mardashev SR, Ia Nikolaev A, Kozlov EA, Potrii OP. Purification of microbial asparaginases by the aid of affinity chromatography. Biokhimiia 1975; 40: 78-82.
18. Ho PP, Milikin EB, Bobbitt JL, Grinnan EL, Burck PJ, Frank BH, et al. Crystalline L-asparaginase from Escherichia coli B. I. Purification and chemical characterization. J Biol Chem 1970; 245: 3708-15.
19. Cooney DA, Capizzi RL, Handschumacher RE. Evaluation of Lasparagine metabolism in animals and man. Cancer Res 1970; 30: 929-35.
20. Souba WW. Glutamine and cancer. Ann Surg 1993; 218: 715-28.
21. Eagle H, Oyama VI, Levy M, Horton CL, Fleischman R. The growth response of mammalian cells in tissue culture to Lglutamine and L-glutamic acid. J Biol Chem 1956; 218: 607-16.
22. Salzman NP, Eagle H, Sebring ED. The utilization of glutamine, glutamic acid, and ammonia for the biosynthesis of nucleic acid bases in mammalian cell cultures. J Biol Chem 1958; 230: 1001-12.
23. Kovacevic Z, Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res 1972; 32: 326-33.
24. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979; 254: 2669-76.
25. Gong SS, Guerrini L, Basilico C. Regulation of asparagine synthetase gene expression by amino acid starvation. Mol Cell Biol 1991; 11: 6059-66.
26. Shan J, Lopez MC, Baker HV, Kilberg MS. Expression profiling after activation of the amino acid deprivation response in HepG2 human hepatoma cells. Physiol Genomics 2010;
27. Bunpo P, Cundiff JK, Reinert RB, Wek RC, Aldrich CJ, Anthony TG. The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase. J Nutr 2010; 140: 2020-7.
28. Bunpo P, Dudley A, Cundiff JK, Cavener DR, Wek RC, Anthony TG. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent Lasparaginase. J Biol Chem 2009; 284: 32742-9.
29. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 2006; 281: 31222-33.
30. Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginaseresistant MOLT-4 human leukaemia cells. Biochem J 2001; 358: 59-67.
31. Bussolati O, Belletti S, Uggeri J, Gatti R, Orlandini G, Dall'Asta V, et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res 1995; 220: 283-91.
32. Rotoli BM, Uggeri J, Dall'Asta V, Visigalli R, Barilli A, Gatti R, et al. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem 2005; 15: 281-92.
33. Tardito S, Uggeri J, Bozzetti C, Bianchi MG, Rotoli BM, Franchi-Gazzola R, et al. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 2007; 60: 751-8.
34. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM. A genomewide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005; 65: 291-9.
35. Kilberg MS, Shan J, Su N. ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab 2009; 20: 436-43.
36. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
37. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-34.
38. Taylor C, Dorr R, Fanta P, Hersh E, Salmon S. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated Lasparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001; 47: 83-8.
39. Agrawal N, Bukowski R, Rybicki L, Kurtzberg J, Cohen L, Hussein M. A Phase I-II trial of polyethylene glycol-conjugated Lasparaginase in patients with multiple myeloma. Cancer 2003; 98: 94-9.
40. Moola ZB, Scawen MD, Atkinson T, Nicholls DJ. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 1994; 302 (Pt 3): 921-7.
41. MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase--past, present, and future. Leuk Lymphoma 1993; 10 Suppl: 153-7.
42. Krasotkina J, Borisova A, Gervaziev Y, Sokolov N. One-step purification and kinetic properties of the recombinant asparaginase from Erwinia carotovora. Biotechnol Appl Biochem 2004; 39: 215-21.
43. Borek D, Jaskólski M. Sequence analysis of enzymes with asparaginase activity. Acta Biochim Pol 2001; 48: 893-902.
44. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006; 107: 4244-9.
45. Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B. Asparaginase-induced derangements of glutamine metabolism: The pathogenetic basis for some drug-related sideeffects. Eur J Clin Invest 1988; 18: 512-6.
46. Bunpo P, Murray B, Cundiff J, Brizius E, Aldrich CJ, Anthony TG. Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice. J Nutr 2008; 138: 338-43.
47. Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004; 24: 1121-5.
48. Offman MN, Krol M, Patel N, Krishnan S, Liu J, Saha V, et al. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 2011; 117: 1614-21.
49. U.S. National Institution of Health. Clinical trials. Available at: http://clinicaltrials.gov. (accessed on March 29, 2011)
50. J. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 1967; 202: 882-8.
51. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwiniaasparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734-9.
52. Perel Y, Auvrignon A, Leblanc T, Vannier J, Michel G, Nelken B, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant. J Clin Oncol 2002; 20: 2774-82.
53. Ishida F, Kwong YL. Diagnosis and management of natural killercell malignancies. Expert Rev Hematol 2011; 3: 593-602.
54. Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003; 44: 879-82.
55. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117: 1834-9.
56. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006; 5: 2613-23.
57. Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, et al. Asparagine synthetase is a predictive biomarker of Lasparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008; 7: 3123-8.
58. Cappelletti D, Chiarelli LR, Pasquetto MV, Stivala S, Valentini G, Scotti C. Helicobacter pylori L-asparaginase: A promising chemotherapeutic agent. Biochem Biophys Res Commun 2008; 377: 1222-6.
59. Scotti C, Sommi P, Pasquetto MV, Cappelletti D, Stivala S, Mignosi P, et al. Cell-cycle inhibition by Helicobacter pylori Lasparaginase. PLoS One 2011; 5: e13892.
60. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, Stigter RL, van Wering ER, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003; 101: 2743-7.
61. Krejci O, Starkova J, Otova B, Madzo J, Kalinova M, Hrusak O, et al. Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia 2004; 18: 434-41.
62. Müller H, Boos J. Use of L-asparaginase in childhood ALL. Critical Reviews in Oncology/Hematology 1998; 28: 97-113.
63. Distasio JA, Salazar AM, Nadji M, Durden DL. Glutaminase-free asparaginase from Vibrio succinogenes: An antilymphoma enzyme lacking hepatotoxicity. Int J Cancer 1982; 30: 343-7.
64. Gallagher MP, Marshall RD, Wilson R. Asparaginase as a drug for treatment of acute lymphoblastic leukaemia. Essays Biochem 1989; 24: 1-40.
65. Killander D, Dohlwitz A, Engstedt L, Franzén S, Gahrton G, Gullbring B, et al. Hypersensitivity reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220-8.
66. Asselin B, Whitin J, Coppola D, Rupp I, Sallan S, Cohen H. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-6.
67. Scotti, C., Valentini, G., Cappelletti, D., Pasquetto, M.V., Stivala S, Chiarelli L.R. L-asparaginase from Helicobacter pylori. WO2010015264 (2010).
68. Durden, D.L. Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence. US6991788 (2006).
69. Distasio JA, Niederman RA, Kafkewitz D, Goodman D. Purification and characterization of L-asparaginase with antilymphoma activity from Vibrio succinogenes. J Biol Chem 1976; 251: 6929-33.
70. Distasio JA, Niederman RA, Kafkewitz D. Antilymphoma activity of a glutaminase-free L-asparaginase of microbial origin. Proc Soc Exp Biol Med 1977; 155: 528-31.
71. Roberts, J., Macallister, T.W., Sethuraman, N., Freeman, A.G. Genetically engineered glutaminase and its use in antiviral and anticancer therapy. US6312939 (2001).
72. Roberts J. Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem 1976; 251: 2119-23.
73. Roberts J, Schmid FA, Rosenfeld HJ. Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of L-glutamine, Ltryptophan, and L-histidine. Cancer Treat Rep 1979; 63: 1045-54.
74. Mononen, I., Kelo, E. Method for treatment of cancers or inflammatory diseases. EP2155237 (2010).
75. Kaartinen V, Mononen T, Laatikainen R, Mononen I. Substrate specificity and reaction mechanism of human glycoasparaginase. The N-glycosidic linkage of various glycoasparagines is cleaved through a reaction mechanism similar to L-asparaginase. J Biol Chem 1992; 267: 6855-8.
76. Noronkoski T, Stoineva IB, Petkov DD, Mononen I. Recombinant human glycosylasparaginase catalyzes hydrolysis of L-asparagine. FEBS Lett 1997; 412: 149-52.
77. Kelo E, Noronkoski T, Mononen I. Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase. Leukemia 2009; 23: 1167-71.
78. Steckel J, Roberts J, Philips FS, Chou TC. Kinetic properties and inhibition of Acinetobacter glutaminase-asparaginase. Biochem Pharmacol 1983; 32: 971-7.
79. Kotzia GA, Labrou NE. L-Asparaginase from Erwinia chrysanthemi 3937: Cloning, expression and characterization. J Biotechnol 2007; 127: 657-69.
80. Warangkar SC, Khobragade CN. Purification, characterization, and effect of thiol compounds on activity of the Erwinia carotovora LAsparaginase. Enzyme Res 2010; 2010: 165878.
81. Kotzia GA, Labrou NE. Cloning, expression and characterisation of Erwinia carotovora L-asparaginase. J Biotechnol 2005; 119: 309-23.
82. Hejazi M, Piotukh K, Mattow J, Deutzmann R, Volkmer-Engert R, Lockau W. Isoaspartyl dipeptidase activity of plant-type asparaginases. Biochem J 2002; 364: 129-36.
83. Derst C, Henseling J, Rohm KH. Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 2000; 9: 2009-17.
84. van der Laan, J.M., Stor, M.C., Lange De, I., Mohrmann, L. Novel asparaginases and uses thereof. WO2008128975 (2008).
85. Zaccolo M, Williams DM, Brown DM, Gherardi E. An Approach to Random Mutagenesis of DNA Using Mixtures of Triphosphate Derivatives of Nucleoside Analogues. J Mole Biol 1996; 255: 589-603.
86. Patel N, Krishnan S, Offman MN, Krol M, Moss CX, Leighton C, et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 2009; 119: 1964-73.
87. Saha, V. Enzyme. WO2007083100 (2007).
88. Ebeid E, Kamel M, Ali B. Detection of anti-asparaginase antibodies during therapy with E. coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma. J Egypt Natl Canc Inst 2008; 20: 127-33.
89. Cheung N, Chau I, Coccia P. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986; 8: 99-104.
90. Feng, J., Wenjie, Z., Wei, G., Chunjia, X., Ning, Z. Polyethylene glycol modified L-asparaginyl amine enzyme. CN101082043 (2006).
91. Armstrong, J.K., Fisher, T.C. Poly (ethylene glycol) anti-body detection assays and kits for performing thereof. WO2008063663 (2008).
92. Armstrong, J.K., Fisher, T.C. Therapeutic methods using pegconjugated agents and devices for performing the same. US20090191175 (2009).
93. Martins MB, Jorge JC, Cruz ME. Acylation of L-asparaginase with total retention of enzymatic activity. Biochimie 1990; 72: 671-5.
94. Cruz, M.E.M., Jorge, J., Martins, M.B., Gaspar, M.M., Esteves, A., Perez-soler, R. Liposomal compositions and processes for their production. EP0485143 (1997).
95. van den Berg H. Asparaginase revisited. Leuk Lymphoma 2011; 52: 168-78.
96. Godfrin, Y. Lysis/resealing process and device for incorporating an active ingredient in erythrocytes. WO2006016247 (2006).
97. Jorge JC, Perez-Soler R, Morais JG, Cruz ME. Liposomal palmitoyl-L-asparaginase: characterization and biological activity. Cancer Chemother Pharmacol 1994; 34: 230-4.
98. Gaspar MM, Perez-Soler R, Cruz ME. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 1996; 38: 373-7.
99. Poznansky MJ, Shandling M, Salkie MA, Elliott JF, Lau E. Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. Cancer Res 1982; 42: 1020-5.
100. Poznansky, M.J. Targeting conjugates of albumin and therapeutic agents. US4749570 (1988).
101. Nan, S., Ronggui, L. Application of rosmarinic acid in Bacillus coli L-asparaginase activator. CN101423827 (2008).
102. Filpula, D.R., Wang, M. Recombinant host for producing LAsparaginase II. US7807436 (2010).
103. Blattner, F.R., Posfai, G., Herring, C.D., Plunkett, G., Glasner, J.D., Twose, T.M. Bacteria with reduced genome. WO03070880 (2003).
104. Campbell, J.W., Blattner, F.R., Plunkett, G., Posfai, G. Reduced genome E. coli. US20090075333 (2009).
105. Noskov, A.N., Noskov, K.A.E., Shishkova, N.A. Plasmid pNAN5 determining synthesis of L-asparaginase EcA2, Bacillus cereus 1576-pNAN5 strain - industrial strain-producer of recombinant Lasparaginase EcA2 and method for its preparing. RU2313575 (2006).
106. Godfrin, Y. Test for predicting neutralization of asparaginase activity. WO2010052315 (2010).
107. Cantor JR, Stone EM, Chantranupong L, Georgiou G. The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. Biochemistry 2009; 48: 11026-31.
108. Bush LA, Herr JC, Wolkowicz M, Sherman NE, Shore A, Flickinger CJ. A novel asparaginase-like protein is a sperm autoantigen in rats. Mol Reprod Dev 2002; 62: 233-47.
109. Ponomarenko J, Bui H-H, Li W, Fusseder N, Bourne P, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 2008; 9: 514.
110. Ansari HR, Raghava GP. Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res 2010; 6: 6.
111. Werner A, Rohm KH, Muller HJ. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Biol Chem 2005; 386: 535-40.
112. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci USA 2011; 108: 1272-7.
113. Zhang YQ, Zhou WL, Shen WD, Chen YH, Zha XM, Shirai K, et al. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates. J Biotechnol 2005; 120: 315-26.
114. Abribat, T. Pegylated L-asparaginase. WO2011003633 (2011).
115. Lorenzi, P.L., Weinstein, J.N., Caplen, N.J. Materials and methods directed to asparagine synthetase and asparaginase therapies. US7985548 (2011).